1 |
ClinicalTrials.gov (NCT03834948) AO-176 in Multiple Solid Tumor Malignancies. U.S. National Institutes of Health.
|
2 |
Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846.
|
3 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
4 |
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-1751.
|
5 |
ClinicalTrials.gov (NCT05626322) A PHASE 1b/2 STUDY OF PF-07901801, A CD47 BLOCKING AGENT, WITH TAFASITAMAB AND LENALIDOMIDE FOR PARTICIPANTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA NOT ELIGIBLE FOR STEM CELL TRANSPLANTATION. U.S.National Institutes of Health.
|
6 |
Clinical pipeline report, company report or official report of KAHR Medical.
|
7 |
Clinical pipeline report, company report or official report of TG Theraputics.
|
8 |
Clinical pipeline report, company report or official report of Shattuck Labs.
|
9 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
10 |
Clinical pipeline report, company report or official report of Trillium Therapeutics.
|
11 |
Clinical pipeline report, company report or official report of Innovent Biologics.
|
|
|
|
|
|
|